ValuEngine lowered shares of Atrion (NASDAQ:ATRI) from a buy rating to a hold rating in a report released on Friday, ValuEngine reports.

Separately, BidaskClub raised shares of Misonix from a buy rating to a strong-buy rating in a research note on Wednesday, July 3rd.

Shares of NASDAQ:ATRI opened at $755.75 on Friday. The company’s 50 day moving average price is $824.13. The stock has a market capitalization of $1.39 billion, a PE ratio of 39.78 and a beta of 0.33. Atrion has a 12 month low of $614.20 and a 12 month high of $948.03.

Atrion (NASDAQ:ATRI) last issued its quarterly earnings data on Wednesday, May 8th. The medical instruments supplier reported $5.07 EPS for the quarter. The company had revenue of $41.61 million during the quarter. Atrion had a net margin of 22.76% and a return on equity of 16.89%.

In other Atrion news, Director Ronald Nicholas Spaulding sold 200 shares of the business’s stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $903.00, for a total value of $180,600.00. Following the completion of the transaction, the director now owns 2,158 shares of the company’s stock, valued at approximately $1,948,674. The transaction was disclosed in a filing with the SEC, which is available through this link. 22.07% of the stock is owned by insiders.

Hedge funds have recently added to or reduced their stakes in the business. Quadrant Capital Group LLC purchased a new position in Atrion in the 1st quarter worth approximately $27,000. O Shaughnessy Asset Management LLC purchased a new position in Atrion in the 1st quarter worth approximately $100,000. Amundi Pioneer Asset Management Inc. purchased a new position in Atrion in the 4th quarter worth approximately $148,000. Paradigm Financial Advisors LLC purchased a new position in Atrion in the 1st quarter worth approximately $211,000. Finally, Legal & General Group Plc grew its stake in Atrion by 7.8% in the 4th quarter. Legal & General Group Plc now owns 249 shares of the medical instruments supplier’s stock worth $185,000 after buying an additional 18 shares in the last quarter. 61.77% of the stock is owned by institutional investors and hedge funds.

About Atrion

Atrion Corporation develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications worldwide. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.

See Also: Why is the LIBOR significant?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.